Partially Silencing Brain Toll-Like Receptor 4 Prevents in Part Left Ventricular Remodeling with Sympathoinhibition in Rats with Myocardial Infarction-Induced Heart Failure

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Ogawa, Kiyohiro ^a   Hirooka, Yoshitaka ^a   Kishi, Takuya ^a   Ide, Tomomi ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NORADRENALIN; RECOMBINANT GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN STEM; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE RELAXATION; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HEMODYNAMICS; LUNG WEIGHT; NONHUMAN; NORADRENALIN URINE LEVEL; PROTEIN EXPRESSION; RAT; SYMPATHETIC BLOCKING; TREATMENT DURATION; TREATMENT RESPONSE; URINARY EXCRETION;

ANIMALS; BODY WEIGHT; BRAIN; CYTOKINES; GENE EXPRESSION REGULATION; GENE SILENCING; HEART FAILURE; HEMODYNAMICS; INFLAMMATION MEDIATORS; MALE; MYOCARDIAL INFARCTION; ORGAN SIZE; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SYMPATHETIC NERVOUS SYSTEM; TOLL-LIKE RECEPTOR 4; VENTRICULAR REMODELING;

MUS; RATTUS;

EID: 84879966917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069053     Document Type: Article

References (35)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823.
2. Ferguson DW, Berg WJ, Sanders JS, (1990) Clinical and hemodynamic correlates of sympathetic nerve activity in normal humans and patients with heart failure: evidence from direct microneurographic recordings. J Am Coll Cardiol 16: 1125-1134.
3. Packer M, (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20: 248-254.
4. Francis GS, (1989) The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J 118: 642-648.
5. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, et al. (1993) Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 88: 136-145.
6. Liu JL, Zucker IH, (1999) Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res 84: 417-423.
7. Patel KP, (2000) Role of paraventricular nucleus in mediating sympathetic outflow in heart failure. Heart Fail Rev 5: 73-86.
8. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, et al. (2003) Heart failure and the brain: new perspectives. Am J Physiol 284: R259-276.
9. Kishi T, Hirooka Y, (2012) Central mechanisms of abnormal sympathoexcitation in chronic heart failure. Cardiol Res Pract 2012: 847172.
10. Ogawa K, Hirooka Y, Kishi T, Sunagawa K, (2011) Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure. J Cardiovasc Pharmacol 58: 543-549.
11. Lindley TE, Doobay MF, Sharma RV, Davisson RL, (2004) Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res 94: 402-409.
12. Yu Y, Zhang ZH, Wei SG, Serrats J, Weiss RM, et al. (2010) Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension 55: 652-659.
13. Yu Y, Zhang ZH, Wei SG, Weiss RM, Felder RB, (2012) Peroxisome proliferator-activated receptor-gamma regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure. Hypertension 59: 477-484.
14. Kang YM, Ma Y, Elks C, Zheng JP, Yang ZM, et al. (2008) Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB. Cardiovasc Res 79: 671-678.
15. Akira S, Takeda K, (2004) Toll-like receptor signaling. Nat Rev 4: 499-511.
16. Takeda K, Kaisho T, Akira S, (2003) Toll-like receptors. Annual Rev Immunol 21: 335-376.
17. Niizeki T, Takeishi Y, Watanabe T, Nitobe J, Miyashita T, et al. (2008) Relation of serum heat shock protein 60 level to severity and prognosis in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 102: 606-610.
18. Kang YM, Zhang ZH, Xue B, Weiss RM, Felder RB, (2008) Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure. Am J Physiol 295: H227-236.
19. Huang BS, Leenen FH, (2005) Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol 288: H2491-2497.
20. Zhang ZH, Yu Y, Wei SG, Felder RB, (2010) Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling. J Hypertens 28: 806-816.
21. Shi P, Raizada MK, Sumners C, (2010) Brain cytokines as neuromodulators in cardiovascular control. Clin Exp Pharmacol & Physiol 37: e52-57.
22. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235.
23. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007.
24. Dargie HJ, (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357: 1385-1390.
25. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, et al. (2002) Carvedilol prospective randomized cumulative survival (COPERNICUS) study group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106: v2194-2199.
26. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13.
27. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, et al. (2005) Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112: 2426-2435.
28. Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, et al. (2010) C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 55: 953-960.
29. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, et al. (2004) Blockade of beta 1- and desensitization of beta 2-adrenoreceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol 485: 227-234.
30. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, et al. (2002) Overexpression of the sarcoplasmic reticulum Ca (2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166-1171.
31. Timmers L, Sluijter JP, van Leulen JK, Hoefer IE, Nederhoff MG, et al. (2008) Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impaires cardiac function after myocardial infarction. Circ Res 102: 257-264.
32. Gueret P, Meerbaum S, Zwehl W, Wyatt HL, Davidson RM, et al. (1981) Two-dimensional echocardiographic assessment of left ventricular stroke volume: experimental correlation with thermodilution and cineangiography in normal and ischemic states. Cathet Cardiovasc Diagn 7: 247-258.
33. Kishi T, Hirooka Y, Sakai K, Shigematsu H, Shimokawa H, et al. (2001) Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension 38: 896-901.
34. Kishi T, Hirooka Y, Ito K, Sakai K, Shimokawa H, et al. (2002) Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension 39: 264-268.
35. Kimura Y, Hirooka Y, Sagara Y, Ito K, Kishi T, et al. (2005) Overexpression of inducible nitric oxide synthase in rostral ventrolateral medulla causes hypertension and sympathoexcitation via an increase in oxidative stress. Circ Res 96: 252-260.